Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Conteltinib + PHA-665752 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Conteltinib | CT-707|CT 707 | ALK Inhibitor 32 FAK inhibitor 15 YAP Inhibitor 3 | Conteltinib (CT-707) is a kinase inhibitor of FAK (PTK2), PYK2 (PTK2B), ALK, and YAP1 (PMID: 29669759), which may result in antitumor activity including inhibition of both tumor growth and metastasis (PMID: 27638856, PMID: 30381078). | |
PHA-665752 | PHA665752|PHA 665752 | MET Inhibitor 59 | PHA-665752 is a small molecule inhibitor of MET, which inhibits MET kinase activity and downstream signaling, potentially resulting in increased apoptosis and decreased proliferation and migration of tumor cells (PMID: 14612533, PMID: 29456739). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|